Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)
NCT ID: NCT01286909
Last Updated: 2011-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
40 participants
INTERVENTIONAL
2011-01-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers
NCT01054508
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
NCT00169559
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
NCT01131299
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
NCT04485793
Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides
NCT00562575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LaFlavon
LaFlavon
two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
Placebo
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LaFlavon
two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Elevated Triglycerides (\> 150)
3. Low High-Density Lipoprotein (HDL) (\< 35)
4. Willingness to take study nutritional supplement once a day for 3 months
Exclusion Criteria
2. Known milk, soy or whey allergy
45 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Omicron Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omicron Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Akram Echtay, M.D.
Role: PRINCIPAL_INVESTIGATOR
Rafic Hariri University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rafic Hariri University Hospital
Beirut, , Lebanon
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Dr. Akram Echtay, M.D.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dr. Akram Echtaye, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OP912011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.